Mirum Pharmaceuticals Files 8-K Report
Ticker: MIRM · Form: 8-K · Filed: May 31, 2024 · CIK: 1759425
Sentiment: neutral
Topics: 8-K, SEC Filing, Corporate Event
TL;DR
Mirum Pharma dropped an 8-K, likely with news. Check it out.
AI Summary
On May 31, 2024, Mirum Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing information regarding "Other Events" without specifying the exact nature of these events in the provided text. The report was filed with the SEC and pertains to the company's operations and corporate actions.
Why It Matters
This filing signals that Mirum Pharmaceuticals has reported a material event to the SEC, which could impact investors' understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: medium — An 8-K filing often contains material information that can significantly impact a company's stock price, necessitating careful review by investors.
Key Numbers
- 001-38981 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-1281555 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Mirum Pharmaceuticals, Inc. (company) — Registrant
- May 31, 2024 (date) — Date of earliest event reported
- SEC (company) — Filing recipient
FAQ
What specific 'Other Events' are being reported by Mirum Pharmaceuticals in this 8-K filing?
The provided text of the 8-K filing does not specify the exact nature of the 'Other Events' being reported, only that this section is being utilized.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on May 31, 2024.
What is Mirum Pharmaceuticals' principal executive office address?
Mirum Pharmaceuticals' principal executive offices are located at 950 Tower Lane, Suite 1050, Foster City, California, 94404.
What is the company's state of incorporation?
Mirum Pharmaceuticals, Inc. is incorporated in Delaware.
What is the SIC code for Mirum Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Mirum Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 686 words · 3 min read · ~2 pages · Grade level 13.8 · Accepted 2024-05-31 17:24:29
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share MIRM Nasdaq Global Market
Filing Documents
- d825353d8k.htm (8-K) — 25KB
- 0001193125-24-151965.txt ( ) — 147KB
- mirm-20240531.xsd (EX-101.SCH) — 3KB
- mirm-20240531_lab.xml (EX-101.LAB) — 18KB
- mirm-20240531_pre.xml (EX-101.PRE) — 11KB
- d825353d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements regarding the anticipated timing of the decision regarding the European Commission's endorsement of the CHMP and COMP positive opinions. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with obtaining regulatory approvals for pharmaceutical product candidates, as well as risks and uncertainties inherent in the Company's business, including those described in the Company's other filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Mirum Pharmaceuticals, Inc. Date: May 31, 2024 By: /s/ Christopher Peetz Christopher Peetz Chief Executive Officer